7th Treg-Directed Therapies Summit
Unravelling Treg Biology, Pioneering Best-in-Class Approaches & Demonstrating Clinical Efficacy to Advance Validated Therapeutic Options in Autoimmunity, Inflammation & Beyond
Over the past year, the Treg sector has seen groundbreaking investments and strategic collaborations between leading biotech and pharma companies like Quell and AstraZeneca, and Parvus and AbbVie, creating a surge of innovation and spotlighting Treg cell therapies and modulators as the next frontier in autoimmune and inflammatory disease treatments. Tregs hold the potential to revolutionize care for conditions that have long lacked effective solutions and are the future of precision medicine in autoimmune and inflammatory diseases.
The 7th Treg-Directed Therapies Summit is your premier event dedicated to exploring and overcoming the unique challenges and advancements specific to Treg. Offering you exclusive access to the latest industry insights, clinical data, Treg biology breakthroughs and strategies for advancing therapies to the clinic from trailblazing companies and academic leaders, including Abata Therapeutics, Harvard Medical School, Nektar Therapeutics, Parvus Therapeutics, PolTreg, ThyTech and many more.
Dates: March 25-27, 2025
Location: Revere Hotel, Boston Common, Boston, Massachusetts
Event Program: https://ter.li/7x3e70
Register your place here (and take advantage of group discounts of up to 20% when registering your team of two or more!): https://ter.li/sb811h
